For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Tafamidis and the formulated version represents a genuine advancement . These innovative therapies protect the transthyretin protein, preventing its damaging build-up and allevia